Search results
Heinz Edgar Lehmann OC FRSC (July 17, 1911 – April 7, 1999) was a German-born Canadian psychiatrist best known for his use of chlorpromazine for the treatment of schizophrenia in 1950s and "truly the father of modern psychopharmacology."
Apr 7, 1999 · Revolutionized the field of psychiatry and established the foundation for psychopharmacology. A pioneer in psychiatric clinical investigation. Dr. Heinz Lehmann has helped shape modern psychiatric care by recognizing the impact of two different drugs on the treatment of mental disorders.
Jan 23, 2017 · In the spring of 1953 at the Verdun Protestant Hospital in Montreal, the psychiatrist Heinz Lehmann initiated the first trial of chlorpromazine in North America, treating “psychomotor excitement” in patients with diagnoses ranging from manic depression to schizophrenia. 1,2 Within weeks, the drug proved a remarkable success: patients ...
People also ask
Who was Heinz Lehmann?
How did Heinz Lehmann shape modern psychiatric care?
Was Heinz Lehmann a good doctor?
What is Lehmann's role in psychopharmacology?
Heinz E. Lehmann, MD. Born in Berlin, in 1911, Lehmann studied at the University of Freiburg and the University of Berlin, from which he graduated in medicine in 1935. He emigrated to Canada in 1937 and assumed clinical duties at the Verdun Protestant Hospital (now Douglas Hospital) in Montreal.
- John M. Oldham
- 2001
I knew Heinz Lehmann as a medical student, as a resident, and then as a faculty member in the McGill Department of Psychiatry. He was a man with strong opinions: one always knew exactly where he stood. In several ways, I felt himtobe a role model. He effectively combined research with clinical care and teaching.
Sep 13, 2021 · Among these remarkable individuals were Frank Berger, Leo Sternbach, and Heinz Lehmann. Their discoveries led to modern psychopharmacology, though the specific drugs they developed are now less...
The credit for this advance is generally accorded to Heinz Lehmann. I sought to explore whether Lehmann really was the first North American psychiatrist to study the effects of chlorpromazine (CPZ) and to provide a more balanced view of its application in a clinical context.
